COVID-19: MACH Response – Archived
Our partners and especially our health services face unprecedented challenges over the next few months. The research response to COVID-19 is second only in importance to the clinical care challenges posed by the epidemic. The MACH has responded by helping our health services and research institutes lead the fight-back by supporting highest priority COVID-19 research.
MACH COVID-19 Activities
The Committee meet regularly to deploy its wide-ranging expertise to review, evaluate and endorse interventional clinical trials for MACH-affiliated health services. The Committee serves as a platform to encourage collaboration across the trials and health services where possible.
Current Committee-endorsed trials are found below with information updated after each Committee meeting:
Factors favouring an endorsement for a trial may include:
- Funding from the NHMRC/MRFF
- An adaptive design
- An opportunity to join an outstanding quality international study
- Studies that nest in biobankable or diagnostic material
- Studies addressing a particular local need
MACH invites partner Research Offices to alert us to studies that are sufficiently advanced to be seeking ethics and governance approval and other queries related to COVID-19 research and trials (including non-clinical trials).
Streamlining ethical approval across MACH
Research Managers (through the statewide Hospital Research Managers Committee) have agreed to fast-track COVID-19 trials through Human Research Ethics Committee (HREC) approval and are reviewing the use of the framework of National Mutual Acceptance (NMA).
Read about the Victorian Collaborative Healthcare Recovery Initiative (VCHRI), a state-wide collaboration between MACH, Monash Partners and Western Alliance, that seeks to develop projects that contribute to the redesign and improvement of Victoria’s healthcare system during recovery from the COVID-19 pandemic through research-led innovation
$3 million for research to accelerate the development of promising COVID-19 prophylactic vaccine candidates for which research and development is already underway. The prophylactic vaccine must be intended to induce active long-term immunity against COVID-19. Now open – Closes 15 July
$1 million for research that characterises the immune response across COVID-19 patients with asymptomatic, mild, moderate, severe, and critical disease. Now open – Closes 23 July
$1 million for research to support research to understand how the mental health system can be enhanced to be most effective and responsive during and following the acute COVID-19 crisis. Now open – Closes 13 July
$4 million for digital health research infrastructure to help health systems respond faster to high-need emerging challenges. Opens 1 July – Closes 14 July
$600,000 for research to understand the community’s information needs and behavioural drivers during outbreaks, and strategies to address these. Opens 1 July – Closes 14 July